Experimental therapeutics and clinical studies in (re)stenosis.
Restenosis is defined functionally as loss of luminal vessel patency following various methods of interventional cardiology, but ultrastructurally, it represents a wound healing response that involves smooth muscle migration, proliferation and matrix deposition at the site of injury. Currently, despite intensive experimental and clinical studies, there are no therapeutic agents that are able to suppress pharmacologically the clinical restenosis. Ultrastructural pathology and animal modeling have played a pivotal role in defining new experimental therapies and rationales for clinical trials. However, concerns regarding the lack of suitable animal models persist and of the many compounds reported efficacious preclinically, none have demonstrated clinical benefit in preventing restenosis. Animal modeling studies now include the use of true restenosis studies, which may be more clinically relevant and pharmacologically predictive of clinical performance.
Handley
D A
DA
Pharmaceuticals Division, Sepracor Incorporated, Marlborough, MA 01752.
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000473:pathology*; D003331:Coronary Vessels / Q000473:pathology*; D004195:Disease Models, Animal; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000473:pathology / Q000648:ultrastructure; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors